Radioactive Drug Research Committee (RDRC)

This committee is established at an institution and approved by the Food and Drug Administration (FDA) for the purpose of approving and monitoring the use of an investigational radioactive drug or biologic for basic human research when the research is not intended for immediate therapeutic, diagnostic, or similar purposes or to determine the safety or effectiveness of the radioactive drug or biologic. When an RDRC has approved the use, the FDA does not require an IND for the use of the investigational radioactive item in the research. See: https://www.fda.gov/drugs/science-and-research-drugs/radioactive-drug-research-committee-rdrc-program